On Feb. 18, 2021, Agilent Technologies announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit intended for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma.

The kit, which marked Agilentﾒs entrance into SARS-CoV-2 testing in the U.S., had completed the notification process to FDA in accordance with Section IV.D of FDAﾒs ﾓPolicy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)ﾔ. The assay was planned to be registered in other markets in 2021 including Canada, Europe, and selected Asia Pacific and Latin American countries.